vs
Side-by-side financial comparison of Arrive AI Inc. (ARAI) and Gain Therapeutics, Inc. (GANX). Click either name above to swap in a different company.
Gain Therapeutics, Inc. is the larger business by last-quarter revenue ($105.4K vs $90.7K, roughly 1.2× Arrive AI Inc.). Arrive AI Inc. runs the higher net margin — -4066.2% vs -4255.7%, a 189.5% gap on every dollar of revenue.
Arrive AI Inc. develops and delivers AI-powered logistics and supply chain optimization solutions. Its core offerings include intelligent route planning, automated load matching, and operational efficiency tools targeted at e-commerce merchants, freight forwarders, and small-to-medium logistics operators across the North American market, helping cut operational costs and shorten delivery cycles.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
ARAI vs GANX — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $90.7K | $105.4K |
| Net Profit | $-3.7M | $-4.5M |
| Gross Margin | — | — |
| Operating Margin | -4066.2% | -4230.3% |
| Net Margin | -4066.2% | -4255.7% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 4.9% |
| EPS (diluted) | $-0.12 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $90.7K | — | ||
| Q3 24 | — | $105.4K | ||
| Q2 24 | — | $84.5K | ||
| Q1 24 | — | $115.3K |
| Q2 25 | $-3.7M | — | ||
| Q3 24 | — | $-4.5M | ||
| Q2 24 | — | $-8.1M | ||
| Q1 24 | — | $-4.0M |
| Q2 25 | -4066.2% | — | ||
| Q3 24 | — | -4230.3% | ||
| Q2 24 | — | -9680.3% | ||
| Q1 24 | — | -3796.7% |
| Q2 25 | -4066.2% | — | ||
| Q3 24 | — | -4255.7% | ||
| Q2 24 | — | -9633.2% | ||
| Q1 24 | — | -3481.4% |
| Q2 25 | $-0.12 | — | ||
| Q3 24 | — | $-0.17 | ||
| Q2 24 | — | $-0.42 | ||
| Q1 24 | — | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $12.0M |
| Total DebtLower is stronger | — | $494.4K |
| Stockholders' EquityBook value | $4.5M | $8.9M |
| Total Assets | $8.5M | $14.4M |
| Debt / EquityLower = less leverage | — | 0.06× |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q3 24 | — | $12.0M | ||
| Q2 24 | — | $16.9M | ||
| Q1 24 | — | $12.7M |
| Q2 25 | — | — | ||
| Q3 24 | — | $494.4K | ||
| Q2 24 | — | $486.4K | ||
| Q1 24 | — | $507.7K |
| Q2 25 | $4.5M | — | ||
| Q3 24 | — | $8.9M | ||
| Q2 24 | — | $11.8M | ||
| Q1 24 | — | $8.6M |
| Q2 25 | $8.5M | — | ||
| Q3 24 | — | $14.4M | ||
| Q2 24 | — | $19.2M | ||
| Q1 24 | — | $14.6M |
| Q2 25 | — | — | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | 0.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.3M | $-6.1M |
| Free Cash FlowOCF − Capex | — | $-6.1M |
| FCF MarginFCF / Revenue | — | -5764.6% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-3.3M | — | ||
| Q3 24 | — | $-6.1M | ||
| Q2 24 | — | $-5.8M | ||
| Q1 24 | — | $-3.6M |
| Q2 25 | — | — | ||
| Q3 24 | — | $-6.1M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q2 25 | — | — | ||
| Q3 24 | — | -5764.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q2 25 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
